Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc (NASDAQ: THTX) is a specialty biopharmaceutical company advancing therapies for HIV complications and oncology conditions. This news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access timely information about FDA-approved HIV treatments like EGRIFTA for lipodystrophy and Trogarzo for multidrug-resistant infections, alongside emerging oncology candidates targeting aggressive cancers. Our curated news collection includes earnings reports, partnership announcements, and research breakthroughs.
Key updates cover three focus areas: commercialized HIV therapies, pipeline progress in oncology, and operational developments across North American/European markets. Content types include clinical trial results, regulatory filings, and executive commentary.
Bookmark this page for structured access to Theratechnologies' latest advancements in niche biopharmaceutical solutions. Verify information directly through company filings and press releases for informed decision-making.
Theratechnologies (THTX) announced positive results from a Phase 3 study of Trogarzo®'s IV Push method for HIV-1 treatment, presented at the virtual CROI on February 12-16, 2022. Key findings include:
- No significant pharmacokinetic differences between IV Push and IV Infusion.
- 94.7% of subjects achieved target drug concentration for both methods.
- No serious adverse events reported, with only one mild treatment-related adverse event noted.
- No difference in HIV-1 viral load or detection of anti-drug antibodies.
The FDA has accepted the supplemental Biologics License Application, with a target action date of October 3, 2022.
Theratechnologies (THTX) announces a strategic shift to an internal sales force, bolstering its U.S. operations. This initiative aims to enhance employee engagement and retention while attracting top talent. The company will integrate key account managers, medical sales liaisons, and community liaisons into its team from a partner contract sales organization. CEO Paul Lévesque emphasizes that this move will improve interactions with customers and drive growth in its commercial franchises, leveraging resumed face-to-face meetings post-COVID.
Theratechnologies Inc. (THTX) announced it will report financial results for its fourth quarter and full fiscal year 2021 on February 24, 2022. A conference call will take place at 8:30 a.m. ET the same day, hosted by CEO Paul Lévesque, to discuss these results and recent business updates. Investors can participate by dialing the provided numbers or accessing the webcast. An audio replay will be available later that day. Theratechnologies focuses on innovative therapies to address unmet medical needs.
Theratechnologies Inc. (NASDAQ: THTX) has announced the submission of a supplemental biologics license application (sBLA) to the FDA for its intravenous (IV) push form of Trogarzo®. This submission follows positive results from the TMB-302 study, which showed no difference in pharmacokinetics between IV Push and IV Infusion. The new administration method allows infusion within 30 seconds without dilution, improving convenience for patients. No serious adverse events were reported, and secondary endpoints confirmed no difference in HIV-1 viral load.
Theratechnologies Inc. (THTX) has won the 2021 Innovation Award in the Life Sciences category at the ADRIQ Innovation Awards Gala held on November 25, 2021. This recognition highlights the company's leadership in innovation within Quebec. Earlier in 2021, THTX received the FDA's Fast-track designation for TH1902, a promising drug targeting advanced solid tumors. The Canadian Cancer Society and the Government of Quebec are supporting THTX's research with a funding commitment of $1.4 million.
Theratechnologies (THTX) announced the filing of a preliminary short form base shelf prospectus in Canada and a corresponding shelf registration statement with the SEC, aiming to restore financing capacity of up to US $150 million. This will allow the potential future offering of various securities over a 25-month period. Additionally, the company plans to renew its US $50 million at-the-market (ATM) facility to take advantage of favorable market conditions. The filings are pending approval from regulatory authorities.
Theratechnologies (TSX: TH, NASDAQ: THTX), a biopharmaceutical company, announced that CEO Paul Levesque will present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021, at 9:40 a.m. ET. Investors can access a live webcast through the investor relations section of Theratechnologies’ website or via a direct link to the virtual conference. An archive of the presentation will be available for 90 days post-event. Theratechnologies focuses on developing innovative therapies for unmet medical needs.
Theratechnologies has secured an agreement with the Italian Medicines Agency (AIFA) for the reimbursement of Trogarzo® for adults with multi-drug resistant HIV-1. This milestone is significant as Italy is the first country with a universal healthcare system to approve the reimbursement for all eligible patients. Trogarzo® is expected to launch in Italy during Q4 2021, following its FDA approval in 2018 and EMA approval in 2019. The company also plans further launches across Europe contingent on reimbursement agreements.
Theratechnologies (TSX: TH, NASDAQ: THTX) announced the publication of a peer-reviewed article in Frontiers in Oncology, showcasing its investigational peptide-drug conjugates (PDCs) TH1902 and TH1904. These PDCs, derived from SORT1+ Technology™, demonstrate efficacy in inhibiting vasculogenic mimicry (VM) in ovarian and triple negative breast cancer models. This is the first report linking SORT1 receptor to VM formation, highlighting the potential of TH1902 and TH1904 as targeted therapies, which may improve drug delivery in cancers with SORT1 overexpression.
Theratechnologies (THTX) reported a 27% increase in Q3 FY2021 consolidated sales compared to Q3 FY2020, totaling $17.85 million. Key driver, EGRIFTA SV®, saw a remarkable 64% sales growth. However, Trogarzo® sales declined by 8%. The ongoing Phase 1 study of TH1902 indicates better tolerability than standard treatments. The company aims to advance its Phase 3 trial for tesamorelin targeting NASH, exploring partnership opportunities. Despite growth, Theratechnologies reported a net loss of $9.51 million for Q3, affected by R&D and selling expenses.
